Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Allergan

U.S. Specialized Therapeutics revenues down 2% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan
1Q Revenues: $3.6 billion (-2%)
1Q Loss: $2.4 billion (loss of $284 million 1Q18)
Comments: U.S. Specialized Therapeutics revenues were $1.5 billion in the quarter, down 2%. BOTOX Therapeutic, BOTOX Cosmetic and JUVÉDERM Collection growth was partially offset by a decline in CoolSculpting sales, lower RESTASIS revenues due to lower net pricing, as well as the divestiture of the Company’s Medical Dermatology business on September 2018. BOTOX Therapeutic sales in the quarter were $397.6 million, up 6%. RESTASIS sales were $231.7 million, down 9%. ALPHAGAN/COMBIGAN sales were $83.0 million, down 1%. OZURDEX revenues were $30.3 million, up 19%. U.S. General Medicine revenues were $1.3 billion, up 2%, primarily due to growth in VRAYLAR and Lo LOESTRIN, partially offset by lower revenues from products that lost exclusivity. VRAYLAR revenues were $143.7 million, up 70%. VIIBRYD/FETZIMA sales were $85.0 million, up 19%. LINZESS sales were $161.3 million, up 1%. Lo LOESTRIN sales were $125.8 million, up 10%. BYSTOLIC/BYVALSON sales were $128.3 million, down 3%.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters